Denali Therapeutics spinout raises $200M as neuro company resets

A new company is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates and raising money from one of its original investors.

The biotech, called Tenvie Therapeutics, launched Wednesday with $200 million from ARCH Venture Partners — one of Denali’s early investors — as well as F-Prime Capital, Mubadala Capital, and others. Denali has an undisclosed equity stake in the new company.

Tenvie is carrying over a collection of small molecule drugs that Denali had been developing but decided to move away from. Executives teased the spinout at the J.P. Morgan Healthcare Conference last year.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Galen robot gets FDA de novo clearance for ENT surgeries

Dive Brief: Galen Robotics, a startup founded in 2016 to commercialize the work of a lab at Johns Hopkins University, said its surgical robot has

September 28, 2023

Incyte cuts final trial for PI3K drug more than a year after yanking accelerated approval filing

Coming off some recent setbacks, Immatics is rolling out its latest update on a new approach to solid tumors that’s bolstered hopes and inspired a

May 3, 2023

IRA lawsuits will test US’ ability to regulate social pricing in pharma – Pharmaceutical Technology

Share this article The Department of Health and Human Services headquarters, Washington, D.C. Photo: Christopher E Zimmer / Shutterstock.com. Lawsuits brought by a range of

January 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.